Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288618 | 0.86 | GPR119 (0.75) | GPR119CYP2C9 | |
| SCHEMBL761736 | 0.85 | GPR119 (0.58) | GPR119CYP2C9 | |
| SCHEMBL2720281 | 0.83 | IRAK4 (0.43) | GPR119CYP2C9 | |
| SCHEMBL516211 | 0.80 | GPR119 (0.61) | GPR119CYP2C9 | |
| SCHEMBL755863 | 0.78 | GPR119 (0.64) | GPR119CYP2C9 | |
| SCHEMBL288167 | 0.77 | GPR119 (0.70) | GPR119CYP2C9 | |
| SCHEMBL3233541 | 0.77 | GPR119 (0.55) | GPR119CYP2C9 | |
| SCHEMBL757761 | 0.77 | GPR119 (0.69) | GPR119CYP2C9 | |
| SCHEMBL288620 | 0.76 | GPR119 (0.56) | GPR119CYP2C9 | |
| SCHEMBL13107758 | 0.76 | GPR119 (0.74) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481731-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8481731-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8481731-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20110021491-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021491-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021491-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021491-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | SLC10A1, NPY4R, CYP4B1 | GPR119 57/4885CYP2C9 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.